The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.31

Today's change-0.05 -3.68%
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.31

Today's change-0.05 -3.68%
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc down (U.S.)$0.05

Arena Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$0.05 or 3.68% to (U.S.)$1.31. Over the last five days, shares have lost 1.50% and are down 7.75% for the last year to date. This security has underperformed the S&P 500 by 34.72% during the last year.

Key company metrics

  • Open(U.S.) $1.36
  • Previous close(U.S.) $1.36
  • High(U.S.) $1.37
  • Low(U.S.) $1.30
  • Bid / Ask(U.S.) $1.30 / (U.S.) $1.35
  • YTD % change-7.75%
  • Volume1,225,879
  • Average volume (10-day)2,091,334
  • Average volume (1-month)3,117,387
  • Average volume (3-month)2,201,765
  • 52-week range(U.S.) $1.13 to (U.S.) $2.16
  • Beta1.63
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.09
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-19.75%

Although this company's net profit margin is negative, it is above the industry average and implies that Arena Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue7851910
Total other revenue--------
Total revenue7851910
Gross profit379167
Total cost of revenue3633
Total operating expense27472936
Selling / general / administrative8799
Research & development16121719
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--2205
Other operating expenses, total--------
Operating income-2138-10-26
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-2238-12-27
Income after tax-2238-12-27
Income tax, total--------
Net income-2239-12-27
Total adjustments to net income--------
Net income before extra. items-2239-12-27
Minority interest000--
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-2239-12-27
Inc. avail. to common incl. extra. items-2239-12-27
Diluted net income-2239-12-27
Dilution adjustment--000
Diluted weighted average shares245243243243
Diluted EPS excluding extraordinary itemsvalue per share-0.090.16-0.05-0.11
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.090.25-0.05-0.09